Analyst firm TD Cowen noted that due to genomic volume growth, Tempus AI benefits from Trump-era tariffs and onshoring trends.

1 report, 1 independent Updated Aug 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

TD Cowen Donald Trump Tempus

Keep exploring

Part of

TD Cowen maintains Buy ratings on Amicus Therapeutics, noting benefits from Trump-era tariffs for certain AI stocks. All 1 developments

The entities involved

TD Cowen
American investment bank
- TD Cowen maintained and revised ratings and price targets for several fintech companies including Klarna, SoFi, Sezzle, Capital One, and Affirm.11:35
- TD Cowen set a hold rating for Klarna on November 2, 2026.11:35
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Voters are showing support for Donald Trump based on the war in Iran, while Democrats are actively seeking political gains in the House of Representatives.12:30
- One of the political figures criticized the current political experiment underway.12:30
Tempus
biotechnology company based in Chicago, Illinois
- Tempus AI and Amazon Web Services are key players in the health tech AI ecosystem.Fri 23:00

Coverage

Newest first; wire copies grouped

Aug 25Insider MonkeyTD Cowen Lifts Tempus AI (TEM) Price Target on Genomic Volumes Growth Tempus AI, Inc. (NASDAQ:TEM) in Cathie Wood's stock portfolio is one of the top 10 stocks to buy now. On August 13, an analyst at